Combining CRP testing and patient information leaflets to safely reduce antibiotic use for acute respiratory tract infections in adults: Protocol for the 2CARE randomised controlled trial in Kyrgyz primary care

结合C反应蛋白检测和患者信息手册,安全有效地减少成人急性呼吸道感染的抗生素使用:吉尔吉斯斯坦基层医疗机构2CARE随机对照试验方案

阅读:1

Abstract

BACKGROUND: Antimicrobial resistance (AMR) is a major health challenge in Kyrgyzstan, where acute respiratory tract infections (ARTIs) are common and frequently treated with antibiotics. Although C-reactive protein (CRP) point-of-care testing can support rational prescribing, there is no consensus on safe CRP thresholds for adults. Patient information leaflets (PILs) may further reduce inappropriate antibiotic use by improving understanding of ARTIs and addressing expectations for antibiotics. The 2CARE trial evaluates whether combining PILs with CRP testing can safely reduce antibiotic use among adults with ARTIs in Kyrgyz primary care. METHODS: 2CARE is a multicentre, open-label, individually randomised controlled trial conducted in 15 primary healthcare centres in Kyrgyzstan. Adults aged 18-70 years with acute respiratory symptoms (<14 days) are randomised 1:1 to receive a PIL or no PIL, and independently 1:1:1 to one of three CRP cut-off levels (20, 40, or 60 mg/L), yielding six parallel groups. Primary outcomes are: (1) total antibiotic use within 21 days, and (2) hospital admission within 21 days. Secondary outcomes include baseline antibiotic prescribing, re-consultations, recovery, hospital referral, antiviral use, and mortality. Analyses will follow the intention-to-treat principle, with per-protocol analysis for non-inferiority, using regression models and generalized estimating equations. A total sample of 1,050 participants provides 90% power for both primary comparisons. DISCUSSION: This trial will generate evidence on the effectiveness of PILs in reducing antibiotic use and establish safe CRP thresholds for adults with ARTIs in a low-resource setting. Findings will inform antimicrobial stewardship policies and guide national CRP implementation in Kyrgyzstan. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT07261969.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。